Sorrento Therapeutics announced that the U.S. Bankruptcy Court for the Southern District of Texas granted approval of Sorrento’s employee wages motion and interim approval of its cash management motion, in connection with Sorrento’s chapter 11 petition, which was filed on February 13, 2023. Sorrento expects to seek approval of other customary "first day" motions in the coming days. Dr. Henry Ji, Ph.D., Chairman and Chief Executive Officer of Sorrento, commented: "We are pleased to have received approvals from the Court for these two motions, which will ensure Sorrento has the ability to continue normal business operations, including the payment of employee wages and benefits, as we move forward-continuing our important work of developing new and innovative therapies for patients struggling with cancer, intractable pain, infectious disease, and more."
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on SRNE:
- Joint Statement by Sorrento Therapeutics, Inc. and Scilex Holding Company on Today’s Isolated Chapter 11 Filing By Sorrento Therapeutics, Inc.
- Scilex says not a debtor in Sorrento’s voluntary Chapter 11 filing
- Sorrento Therapeutics downgraded to Neutral from Buy at Dawson James
- Sorrento Therapeutics files for Chapter 11 bankruptcy in Texas
- Scilex Holding Company, a majority-owned subsidiary of Sorrento Therapeutics, Inc., acquires rights to FDA-Approved ELYXYB™ in the U.S. and Canada for the acute treatment of migraine